Shanghai HeartCare Medical Technology Intracranial Stent Registration Application Accepted by NMPA

Reuters
01/20
Shanghai HeartCare Medical Technology Intracranial Stent Registration Application Accepted by NMPA

Shanghai HeartCare Medical Technology Corporation Ltd. announced that its registration application for a Self-expanding Intracranial Drug-eluting Stent has been accepted by the National Medical Products Administration (NMPA) of the People's Republic of China. The device is intended for the treatment of intracranial atherosclerotic stenosis and aims to provide support and recanalization of stenotic and occluded lumens while preventing in-stent restenosis. According to the company, similar products have not yet been approved for marketing worldwide. The company cautioned that there is no assurance the product will ultimately be successfully commercialized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260120-11996453), on January 20, 2026, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10